Umass Memorial Medical Center - University Campus 55 Lake Ave N, Worcester, MA 01655UPMC Latterman Family Health Center 5200 Centre Ave, Pittsburgh, PA 15232Eye & Ear Institute 200 Lothrop St, Pittsburgh, PA 15213
Dr. Alec E Vaezi, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Ear, Nose, and Throat
Address:
5200 Centre Ave SUITE 211, Pittsburgh 15232 (412) 621-0123 (Phone) UNIVERSITY OF MASSACHUSETTS MEMORIAL MEDICAL CENTER 55 Lake Ave N, Worcester 01655 (508) 334-3206 (Phone), (508) 856-4668 (Fax)
Certifications:
Otolaryngology, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
5200 Centre Ave SUITE 211, Pittsburgh 15232 UNIVERSITY OF MASSACHUSETTS MEMORIAL MEDICAL CENTER 55 Lake Ave N, Worcester 01655 Upmc Mercy 1400 Locust St, Pittsburgh 15219 UPMC Passavant - Cranberry 1 Saint Francis Way, Cranberry Twp 16066 Upmc Shadyside 5230 Center Ave, Pittsburgh 15232
Use Of Choline-Phosphate Cytidylyltransferase-Alpha (Cct-Alpha) As A Biomarker For Cancer Prognosis
US Patent:
2013020, Aug 8, 2013
Filed:
Feb 4, 2013
Appl. No.:
13/758780
Inventors:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA, US Nikhil Ramchandra Bhagwat - Pittsburgh PA, US Alec E. Vaezi - Pittsburgh PA, US
International Classification:
G01N 33/68
US Classification:
424 946, 435 74, 435 613, 435 612, 506 9, 435 611
Abstract:
It has previously been demonstrated that positive 8F1 immunohistochemistry is an indicator of a poor cancer prognosis and poor response to chemotherapy. The 8F1 antibody was generated by immunization against ERCC1, a DNA repair protein, but recognizes a second, previously unidentified protein in cells and tissues. Disclosed herein is the finding that in addition to ERCC1, the 8F1 antibody recognizes the choline phosphate cytidylyltransferase-α (CCTα) protein. Thus, provided herein is a method of determining the prognosis of a patient with cancer by specifically detecting expression of CCTα in a sample obtained from the subject. Also provided is a method of predicting the response of a cancer patient to treatment with a genotoxic therapy by specifically detecting expression of CCTα in a sample obtained from the subject.